Spark Biomedical Secures Wellcome Leap Funding to Advance Women's Health Neurostimulation Technology
Spark Biomedical's recent funding from Wellcome Leap will enable FDA-style clinical trials for its OhmBody wearable neurostimulation device, which has shown promising results in reducing menstrual bleeding and symptoms, representing a significant advancement in addressing long-neglected women's health needs.
Spark Biomedical, under the leadership of President and CEO Daniel Powell, has received significant funding from Wellcome Leap to advance its women's health innovation initiatives. This funding represents a critical milestone for the company, enabling it to conduct an FDA-style clinical study that serves as the final step toward obtaining FDA clearance and CE mark approval for its OhmBody wearable neurostimulation device.
The company's work in women's health began with a pivotal research discovery in 2023 when Spark licensed research and patents to use neurostimulation for improving hemostasis. Initial clinical trials applying this technology to women with heavy menstrual bleeding yielded remarkable results, showing a 55% reduction in blood loss and a 20% shorter cycle time. Participants also reported significant reductions in cramping and improvements in energy and mood, indicating the technology's potential as a comprehensive menstrual solution.
Daniel Powell, who has over 25 years of experience in medical devices and specifically neurostimulation, explained that Spark's approach combines both trigeminal and vagus nerve stimulation to address brain imbalances. The company's mission extends beyond menstrual wellness to target other women's health conditions including endometriosis, PCOS, and menopause. Powell emphasized that women's health has been severely neglected for too long, and Spark aims to make a profound impact through wearable neurostimulation technology.
The Wellcome Leap funding is particularly significant as Spark Biomedical was the only non-research institution among the awardees, which Powell attributes to the clinical validity of the team's work. The company faces typical challenges in the medtech space, including changing consumer behaviors toward pill-based solutions and navigating complex regulatory and reimbursement systems through organizations like the FDA and CMS.
Looking forward, Spark plans to expand its OhmBody offering to address additional women's health conditions while continuing to develop hemostasis solutions for non-compressible hemorrhages, surgical applications, and traumatic blood loss. The company's partnership strategy focuses on scientific rigor, which has been key to building successful collaborations with researchers, healthcare providers, and funders.